Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEland Oil & Gas Regulatory News (ELA)

  • There is currently no data for ELA

Opuama Work Programme Confirmed

9 Nov 2017 07:00

RNS Number : 9884V
Eland Oil & Gas PLC
09 November 2017
 

 9 November 2017

 

Eland Oil & Gas PLC

("Eland" or the "Company")

 

Opuama Work Programme Confirmed

 

Eland Oil & Gas PLC (AIM: ELA), an oil & gas production and development company operating in West Africa with an initial focus on Nigeria, is pleased to announce that, in light of the extremely successful operation on OP7, the OML 40 joint-venture partnership has committed to the drilling of the Opuama-9 and Opuama-10 infill wells on Opuama field. Eland's joint-venture Company, Elcrest Exploration and Production Nigeria Ltd ("Elcrest"), has signed a rig contract with OES Energy Services Limited ("OES"), for the OES Teamwork Rig for this upcoming continuous drilling campaign.

 

Once drilling is complete at Opuama-8, the OES Teamwork Rig will mobilise to the Opuama-9 drill site and commence operations, expected in January 2018, before moving to the Opuama-10 drill site. Upon completion of drilling, Opuama-9 and Opuama-10 are expected to contribute initial production rates of 4,000 to 6,000 barrels of oil per day ("bopd") each. This increases the potential near term overall production from OML 40 to around an expected 30,000 bopd gross.

 

George Maxwell, CEO of Eland, commented:

"Completion of the Opuama infill drilling campaign has the potential to increase OML 40's gross production to over 30,000 barrels of oil per day in H1 2018. This is an over tenfold increase in reported production, taking place in under two and a half years. Securing the sustained drilling program for OML 40 will drive the Company forward to become one of the largest, by production volume, E&P Companies on AIM. With increasing production and an improving oil price, our netbacks from OML 40 will significantly drive our net cash generation.

 

There is strong momentum within the Company and with Elcrest's partner NPDC within the OML 40 joint-venture and we look forward to updating the market on the result of our Opuama drilling campaign as the infill drilling campaign progresses."

 

END

 

For further information:

 

Eland Oil & Gas PLC (+44 (0)1224 737300)

www.elandoilandgas.com

George Maxwell, CEO

Ronald Bain, CFO

Finlay Thomson, IR

 

Canaccord Genuity Limited (+44 (0)20 7 523 8000)

Henry Fitzgerald O'Connor / James Asensio

 

Panmure Gordon (UK) Limited (+44 (0)20 7 886 2500)

Adam James / Atholl Tweedie

Tom Salvesen

 

Camarco (+44 (0) 203 757 4980)

Billy Clegg / Georgia Edmonds / Tom Huddart

 

 

In accordance with the guidelines of the AIM Market of the London Stock Exchange, Pieter van der Groen, a geologist and Eland's Chief Operating Officer, who has a geology degree from Auckland University, a Masters degree in Petroleum Geology from the University of Aberdeen and has over 25 years of relevant experience in the upstream oil and gas industry and who is a member of the Society of Petroleum Engineers and meets the criteria of qualified person under the AIM guidance note for mining and oil and gas companies, has reviewed and approved the technical information contained in this announcement.

 

Notes to editors:

Eland Oil & Gas is an AIM-listed independent oil and gas company focused on production and development in West Africa, particularly the highly prolific Niger Delta region of Nigeria.

Through its joint venture company Elcrest, Eland's core asset is OML 40 which is located in the Northwest Niger Delta approximately 75km northwest of Warri and has an area of 498km². In addition, the Company has a 40% interest in the Ubima Field, onshore Niger Delta, in the northern part of Rivers State.

The OML 40 licence holds gross 2P reserves of 83.2 mmbbls, gross 2C contingent resources of 41.2 mmbbls and a best estimate of 254.5 mmbbls of gross unrisked prospective resources. The Ubima field holds gross 2P reserves of 2.4 mmbbls of oil and gross 2C resource estimates of 31.1 mmbbl.

Net production figures relate to Elcrest Exploration and Production Nigeria Ltd ("Elcrest"), Eland's joint venture company. Production rates, are as measured at the Opuama PD meter, are subject to reconciliation and will differ from sales volumes.

 

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STRBPBBTMBMMTLR
Date   Source Headline
17th Jul 20095:57 pmBUSStudies Presented at International Conference on Alzheimer's Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimer's Disease
16th Jul 20092:18 pmRNSResults of Annual General Meeting
13th Jul 200911:30 amBUSElan and Transition Therapeutics Announce Phase 1 Data Showing ELND005 Achieves Desired Concentrations in Brain Tissue and Cerebrospinal Fluid
10th Jul 20094:59 pmRNSCancellation of UK Listing
8th Jul 20097:00 amBUSElan Announces Webcast of Second Quarter 2009 Financial Results
3rd Jul 200910:57 amRNSBlock Listing Six Monthly Return
2nd Jul 200912:57 pmRNSHolding in Company
2nd Jul 200912:41 pmPRNJohnson & Johnson, Elan Announce Definitive Agreement
1st Jun 20097:00 amBUSSubset Data from Two Randomized Phase 3 Trials Show TYSABRI® Significantly Improves Health-Related Quality of Life for Crohn's Disease Patients with Prior Exposure or Inadequate Response to Anti-TNF? Therapy
29th May 20094:36 pmRNSPrice Monitoring Extension
29th May 20092:00 pmBUSRenee P. Tannenbaum, Pharm.D. Joins Elan as Executive Vice President and Chief Commercial Officer
29th May 200911:54 amBUSTotal Voting Rights
30th Apr 200912:16 pmBUSTotal Voting Rights
27th Apr 20093:35 pmRNSAnnual Report
14th Apr 20095:09 pmRNSHolding(s) in Company
27th Feb 20092:44 pmBUSTotal Voting Rights
25th Feb 200912:23 pmBUSDirector/PDMR Shareholding
12th Feb 20096:00 pmBUSDirector/PDMR Shareholding
12th Feb 20096:00 pmBUSDirector/PDMR Shareholding
9th Feb 20097:00 amBUSMS Patients Treated with TYSABRI® Remain Free of Disease Activity for Two Years, According to Data Published in the Lancet Neurology
4th Feb 20092:32 pmRNSHolding(s) in Company
3rd Feb 20093:57 pmRNSHolding(s) in Company
30th Jan 20094:33 pmRNSHolding(s) in Company
28th Jan 20094:24 pmRNSHolding(s) in Company
13th Jan 20097:00 amBUSElan Clarifies Duration of Bapineuzumab Phase 3 Trials
12th Jan 20095:21 pmRNSHolding(s) in Company
12th Jan 20097:00 amBUSTysabri Update
2nd Jan 200912:21 pmRNSTotal Voting Rights
18th Dec 20084:24 pmRNSBlock Listing Six Monthly Return
16th Dec 200811:00 amBUSDirector Declaration
16th Dec 20087:00 amBUSElan to Present at the 27th Annual JP Morgan Healthcare Conference
15th Dec 20083:02 pmBUSTysabri Update
12th Dec 20087:00 amBUSElan Announces Resource Realignment
28th Nov 200810:47 amBUSTotal Voting Rights
25th Nov 20087:00 amBUSMary Stutts to Join Elan as Senior Vice President and Head of Corporate Relations
20th Nov 20087:00 amBUSCarlos V. Paya, MD, PhD, to Join Elan as Company President
3rd Nov 20085:12 pmRNSDirector/PDMR Shareholding
31st Oct 20084:11 pmRNSHolding in Company
31st Oct 200812:01 pmRNSTotal Voting Rights
30th Oct 20084:13 pmRNSTysabri Update
3rd Oct 20085:56 pmRNSHolding in Company
30th Sep 20084:11 pmRNSTotal Voting Rights
22nd Sep 200811:26 amRNSHolding In Company
22nd Sep 20087:00 amRNSTysabri Demonstrates Sustained Improvement
11th Sep 20087:39 amRNSDirector /PDMR Shareholding
1st Sep 20085:02 pmRNSHolding(s) in Company
29th Aug 200810:54 amRNSTotal Voting Rights
28th Aug 20087:00 amRNSInterim Results
14th Aug 20084:12 pmRNSHolding in Company
13th Aug 20085:22 pmRNSHolding in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.